New Seer Technology Access Center to open in Bonn, Germany

新的Seer技术访问中心将在德国波恩开幕

Provides life sciences researchers conducting proteomic studies full-service access to the Seer Proteograph™ Product Suite and mass spectrometry

为进行蛋白质组学研究的生命科学研究人员提供Seer Proteograph™产品套件和质谱的全方位服务

REDWOOD CITY, Calif., May 08, 2024 (GLOBE NEWSWIRE) -- Seer, Inc. (Nasdaq: SEER), a leading life sciences company commercializing a disruptive new platform for proteomics, announced the launch of the Seer Technology Access Center (STAC) in Bonn, Germany, providing the European biopharma and life sciences communities with service programs and the latest mass spectrometry technologies to optimize deep, unbiased proteomic studies.

加利福尼亚州红木市，2024年5月8日（环球通讯社）--领先的生命科学公司Seer，Inc.（纳斯达克：Seer）将颠覆性的蛋白质组学新平台商业化，宣布在德国波恩成立Seer技术访问中心（STAC），为欧洲生物制药和生命科学界提供服务计划和最新的质谱技术，以优化深度，无偏见的蛋白质组学研究。

The new facility, opening in June, will be located at Life & Brain GmbH, an independent commercial technology provider, on the campus of the University Hospital Bonn. In June 2023, Seer established the first Seer Technology Access Center at the company’s headquarters in Redwood City, California..

新设施将于6月开放，位于波恩大学医院校园内的独立商业技术提供商Life＆Brain GmbH。2023年6月，Seer在位于加利福尼亚州红木市的公司总部建立了第一个Seer技术访问中心。。

The Seer Technology Access Center in Europe will help address an unmet need for researchers who want to conduct deep, unbiased proteomics studies to accelerate biomarker discovery and drug development. The Center provides multiple programs designed to accelerate broad availability of state-of-the-art unbiased proteomics technologies for those seeking to extend the scope of their research, get results faster, and pursue answers to critical biology.

欧洲的Seer技术访问中心将帮助解决希望进行深入，无偏见的蛋白质组学研究以加速生物标志物发现和药物开发的研究人员未满足的需求。该中心提供多个项目，旨在为那些寻求扩大研究范围，更快获得结果并寻求关键生物学答案的人加速最先进的无偏见蛋白质组学技术的广泛可用性。

At the new facility in Bonn, scientists will have access to Seer’s ProteographTM Product Suite, including the new Proteograph XT Assay Kit, and the latest liquid chromatography-mass spectrometry technologies, all supported by Seer’s world-class technical and scientific team..

在波恩的新设施中，科学家将可以使用Seer的ProteographHTM产品套件，包括新的Proteograph XT分析试剂盒和最新的液相色谱-质谱技术，所有这些都得到了Seer世界级技术和科学团队的支持。。

“At Seer, our commitment lies in facilitating our clients' seamless access to unbiased proteomics, enabling deep biological insights into health and disease as well as model organism studies,” said Omid Farokhzad, CEO and Chair at Seer. “Our European STAC is tailored to meet the needs of our biopharma customers and collaborators, helping them make proteomic discoveries deeper and faster than ever before with our Proteograph XT Assay and the latest mass spec technologies, potentially leading to the development of more effective medicines and accurate biomarkers.”.

Seer首席执行官兼主席奥米德·法罗克扎德（OmidFarokhzad）表示：“在Seer，我们的承诺在于促进我们的客户无缝访问无偏见的蛋白质组学，从而能够深入了解健康和疾病以及模式生物研究。”。“我们的欧洲STAC旨在满足我们生物制药客户和合作者的需求，通过我们的Proteograph XT分析和最新的质谱技术，帮助他们比以往任何时候都更深入更快地进行蛋白质组学发现，从而有可能开发出更有效的药物和准确的生物标志物。”。

“We adopted Seer’s Proteograph platform at Life & Brain more than a year ago and are very impressed by the performance of the Proteograph XT Assay,” said Dr. Per Hoffmann, CCO of Life & Brain. “I am delighted that Seer is using Life & Brain’s facilities to establish the European STAC as this is very complementary to our own proteomics efforts.

“一年多前，我们在Life＆Brain采用了Seer的Proteograph平台，Proteograph XT分析的性能给我们留下了深刻的印象，”Life＆Brain CCO Per Hoffmann博士说。“我很高兴Seer正在使用Life&Brain的设施建立欧洲STAC，因为这与我们自己的蛋白质组学工作非常互补。

We have seen great interest in our customer base to add proteomics in addition to our genomics service offerings.”.

除了我们的基因组学服务之外，我们的客户群对添加蛋白质组学非常感兴趣。”。

The STAC in Bonn will launch in June with multiple Proteograph SP100 automation instruments running the Proteograph XT Assay leveraging multiple mass spectrometers. Hundreds of samples per week can be processed on a fully automated workflow with minimal hands-on time, allowing unbiased detection of low abundant proteins and isoforms in complex biosamples that has not been possible before.

波恩的STAC将于6月推出多个Proteograph SP100自动化仪器，利用多个质谱仪运行Proteograph XT分析。每周可以在全自动工作流程上处理数百个样品，而动手时间最短，从而可以无偏见地检测复杂生物样品中的低丰度蛋白质和同工型，这在以前是不可能的。

The workflow increases both throughput and performance substantially, lowering the cost per data point, and thereby enabling more labs to access the power they need to unlock the potential of the proteome..

该工作流程大大提高了吞吐量和性能，降低了每个数据点的成本，从而使更多的实验室能够获得释放蛋白质组潜力所需的能力。。

To learn more about Seer’s Technology Access Center, contact your local Seer representative by requesting a consultation at www.seer.bio.

要了解有关Seer技术访问中心的更多信息，请访问www.Seer.bio咨询您当地的Seer代表。

About Seer

关于Seer

Seer is a life sciences company developing transformative products that open a new gateway to the proteome. Seer’s Proteograph Product Suite is an integrated solution that includes proprietary engineered nanoparticles, consumables, automation instrumentation and software to perform deep, unbiased proteomic analysis at scale in a matter of hours.

Seer是一家生命科学公司，正在开发变革性产品，为蛋白质组开辟新的门户。Seer的Proteograph产品套件是一个集成解决方案，包括专有的工程纳米颗粒，消耗品，自动化仪器和软件，可在数小时内进行深度，无偏见的蛋白质组学分析。

Seer designed the Proteograph workflow to be efficient and easy to use, leveraging widely adopted laboratory instrumentation to provide a decentralized solution that can be incorporated by nearly any lab. Seer’s Proteograph Product Suite is for research use only and is not intended for diagnostic procedures.

Seer将Proteograph工作流程设计为高效且易于使用，利用广泛采用的实验室仪器提供了一个分散的解决方案，几乎可以被任何实验室合并。Seer的Proteograph产品套件仅用于研究用途，不用于诊断程序。

For more information, please visit www.seer.bio..

有关更多信息，请访问www.seer.bio。。

Forward-Looking Statements

前瞻性声明

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995, as amended. Such forward-looking statements are based on Seer’s beliefs and assumptions and on information currently available to it on the date of this press release.

本新闻稿包含1995年《私人证券诉讼改革法案》修订版所指的“前瞻性声明”。此类前瞻性声明基于Seer的信念和假设以及截至本新闻稿发布之日的现有信息。

Forward-looking statements may involve known and unknown risks, uncertainties and other factors that may cause Seer’s actual results, performance, or achievements to be materially different from those expressed or implied by the forward-looking statements. These and other risks are described more fully in Seer’s filings with the Securities and Exchange Commission (“SEC”) and other documents that Seer subsequently files with the SEC from time to time.

前瞻性陈述可能涉及已知和未知的风险、不确定性和其他因素，这些因素可能导致Seer的实际结果、绩效或成就与前瞻性陈述中明示或暗示的结果、绩效或成就存在重大差异。Seer向美国证券交易委员会（“SEC”）提交的文件以及Seer随后不时向SEC提交的其他文件中更全面地描述了这些风险和其他风险。

Except to the extent required by law, Seer undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made..

除非法律要求，Seer没有义务更新此类报表，以反映报表编制日期后发生的事件或情况。。

Investor Contact:

投资者联系人：

Carrie Mendivil

Carrie Mendivil

investor@seer.bio

investor@seer.bio

Media Contact:

媒体联系人：

Patrick Schmidt

帕特里克·施密特

pr@seer.bio

pr@seer.bio